Ken Griffin Lyra Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.24 - $0.34 $552 - $782	-2,300 Reduced 9.83%	21,100 $5,000
Q2 2024 Aug 14, 2024	BUY	$0.26 - $6.25 $3,822 - $91,875	14,700 Added 168.97%	23,400 $6,000
Q1 2024 May 15, 2024	BUY	$4.55 - $6.53 $33,215 - $47,669	7,300 Added 521.43%	8,700 $54,000
Q4 2023 Feb 14, 2024	SELL	$2.82 - $5.24 $12,972 - $24,104	-4,600 Reduced 76.67%	1,400 $7,000
Q3 2023 Nov 14, 2023	BUY	$2.95 - $4.8 $9,145 - $14,880	3,100 Added 106.9%	6,000 $23,000
Q2 2023 Aug 14, 2023	SELL	$1.98 - $4.33 $2,772 - $6,062	-1,400 Reduced 32.56%	2,900 $11,000
Q1 2023 May 15, 2023	BUY	$1.95 - $3.09 $7,800 - $12,360	4,000 Added 1333.33%	4,300 $8,000
Q4 2022 Feb 14, 2023	BUY	$2.44 - $5.42 $732 - $1,626	300 New	300 $0

32.2M

21.1K

400

Ticker LYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,826,400
Market Cap $6.05M
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.